Genomic Biochemical Engineering | | Cell Culture Engineering | Metabolic Pathway Engineering | Liver Cell Self Assembly | Analysis of Bioreaction Network | Stem Cell Culture Engineering | Image Processing in Fluorescence Microscopy | Bioartificial Liver | MAIN RESEARCH PAGE


BAL page

How it works

Results

Current People

The University of Minnesota Bioartificial Liver

The liver is a major factory in our bodies.  It produces many proteins, including albumin and clotting factors.  It also balances the chemical environment, including glucose and amino acid concentrations, and it metabolizes or detoxifies many drugs and waste products of the body's metabolism. Because of the liver's structural complexity and functional diversity, our quest for finding an artificial replacement or semi-synthetic surrogate has been elusive. Liver failure is the 7th leading cause of death in the United States (American Liver Foundation, 1996).  Over thirty thousand people die of liver failure every year in the United States alone. Mortality rates are particularly high for those diagnosed with acute fulminant hepatic failure (FHF) because hepatic regeneration is neither rapid nor sufficient enough to sustain the patient.  Those who qualify for a liver transplant often die while awaiting an allograft because of the scarcity of donor organs.  Thus there is a critical need for improved temporary liver support for potential transplant recipients, as well as for patients with reversible, acute hepatitis who do not qualify for liver transplantation.

Currently, the only treatment for acute liver failure is liver transplantation. However, the supply of transplantable organs is far short of the demand. A bioartificial liver (BAL) device employing isolated liver cells, or hepatocytes, can potentially provide temporary support for patients in liver failure. A multidisciplinary team of researchers here at the University of Minnesota has developed a BAL device to treat patients in acute liver failure. It is designed to be a bridge therapy, to support or stabilize patients until a transplantable organ becomes available or until their own liver can regenerate.

Recently, our BAL technology was licensed to Algenix, Inc. With financial support from Algenix, the University of Minnesota team is preparing to begin phase I clinical trials later this year.